AzTrials
AzTrials

Cerebral PalsytooluseNCT06531330

Use of Tools for Early Detection of Cerebral Palsy

An observational study of Cerebral Palsy and Early Developmental Impairment, run by Kahramanmaras Sutcu Imam University at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

High risk of infant is defined as an infant who has a history of negative environmental and biological factors and these factors can cause neuromotor development problems. This group is a heterogeneous group that includes premature babies born under thirty-seven weeks, term babies with low birth weight (LBW), or… Read more about this study

Who is it for?
Ages 25 to 50 yearsHealthy volunteers can take part
How many people
140 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Mar 2023to 15 Apr 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Study population: Physiotherapists who have been working in the field of pediatric physiotherapy for at least 3 years and aged between 25-50 years old will be included in the study.Physiotherapists with any psychiatric diagnosis will be excluded.

Who may be able to join

  • Physiotherapists who have been working in the field of pediatric physiotherapy for at least 3 years

Who cannot join

  • Physiotherapists with any psychiatric diagnosis

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Hatice

    Kahramanmaraş, 46100

Other trials in Turkey (Türkiye)

About this study

Official title: Use of Tools for Early Detection of Cerebral Palsy: A Study on Pediatric Physiotherapists in Turkey

High risk of infant is defined as an infant who has a history of negative environmental and biological factors and these factors can cause neuromotor development problems. This group is a heterogeneous group that includes premature babies born under thirty-seven weeks, term babies with low birth weight (LBW), or babies with developmental delays for various reasons. These infants are also monitored for Cerebral Palsy (CP). CP is the most common physical disability in childhood, with an incidence of 2.1 per 1000 births.In a 2017 clinical review of early diagnosis tools, a group of international experts published best practice recommendations, calling for early diagnosis to be made as a result of timely use of the recommended tools. The diagnosis of CP is typically made by a physician between 12 and 24 months of age, but in some cases it is delayed until 42 months.Correct and early use of the key tools required for early diagnosis may allow much earlier detection of CP for infants younger than 5 months or older.Early detection and monitoring of infants in the community for CP is essential only with appropriate, valid and reliable tools in order to minimize possible sequelae through timely implementation of CP-specific interventions. According to international guidelines, babies with high risk of CP should be followed up. This follow-up should be done by an interdisciplinary team such as neonatologist, pediatrician, pediatric neurologist, physiotherapist, speech-language-swallowing therapist, and special education specialist. Pediatric physiotherapists are an important part of this team in terms of developmental follow-up and rehabilitation. Therefore, it is important that the awareness level of pediatric physiotherapists in this field in our country is sufficient, they are equipped with various trainings and reach the international level. In this way, families at risk of CP can provide early guidance for their children, ensure early diagnosis of CP, and initiate treatment.The aim of this study is to evaluate the use of early diagnostic evaluation tools in at-risk of infants between the ages of 0-2 at risk of CP in pediatric physiotherapy practice in Turkey.

Read the detailed description

Prematures make up the majority of risky babies; perinatal asphyxia, hypoxic ischemic encephalopathy (HIE), periventricular leukomalacia (PVL), intraventricular hemorrhage (IVH), respiratory distress syndrome (RSD), bronchopulmonary dysplasia (BPD), hyperbilirubinemia, viral infections, fetal alcohol syndrome, muscle tone disorders, hydrocephalus and They may encounter risk factors such as microcephaly.It is important to detect early atypical neurodevelopmental findings that may occur in at-risk of infants at later ages and direct them to the necessary intervention programs.In this context, all healthcare professionals in the follow-up of at-risk babies should follow developmental and medical follow-up guidelines and use various neuromotor assessment methods. It is also stated in the guidelines of the American Academy of Pediatrics (APA) and the high-risk baby monitoring guide of the Turkish Neonatology Association that these babies should be monitored periodically by a team.The importance of monitoring all premature infants, especially very low birth weight (VLBW) babies <1500g, at least twice in the first year of their lives, with age-appropriate neuromotor and developmental evaluations is emphasized. In this way, infants; By determining motor, sensory, cognitive and social developmental delays, developmental problems in later ages can be predicted. In addition, physiotherapy and rehabilitation or special education needs can be determined in terms of early intervention and motor development, and early referral to appropriate support programs can be provided.The 3 methods with the best predictable validity that can determine CP before the corrected 5-month period are; Neonatal MRI (86%-89% sensitivity), Prechtl's GMs Evaluation (98% sensitivity), HINE (90% sensitivity). Using the HINE test alone was also found to be reliable in determining the development of CP. In recent years, studies have shown that the diagnosis of high-risk CP can be detected at the 3rd month with predictive validity and reliability by evaluating the quality of Prechtl's GMs movements.Early physiotherapy and rehabilitation in CP includes approaches starting from the neonatal period and up to 24 months. The main aim is to provide normal functional movements and normal sensory input by using the rapid learning ability resulting from brain plasticity.Velde et al. In order to implement a new evidence-based clinical guideline for early diagnosis in Australia, a study aimed to determine the age at diagnosis, suitability for recommended tests, and acceptability of the early diagnosis clinic for parents and referrers, by following patients according to international guidelines, estimated CP diagnosis between 4-8 months. They showed. The follow-up clinic in this study was found to be highly acceptable to parents and referrers. During this follow-up period, pediatricians had the highest referral rates (39%), followed by auxiliary healthcare professionals (31%), primary caregivers (14%) and other healthcare professionals (16%).In a study conducted among American pediatricians, it was stated that there was uncertainty about how to diagnose and refer babies with motor delays, and variability in knowledge and practices regarding the identification of motor delays in these babies. A study conducted with clinicians (pediatricians, physiotherapists and occupational therapists) in New Zealand investigated current clinical practices regarding awareness and use of diagnostic tools for the detection of CP. Despite high awareness of the risk of CP in New Zealand, current use of international best practice tools in the clinic has been observed to be low. Clinicians who do not make diagnoses within their professional roles also reported that the assessment tools were rarely used, with 74% never using GMs or HINE and 54% in assessing children at risk for CP. Barriers to use have been cited as lack of time or funding, lack of clear guidelines, and inadequate management support. In a study conducted with pediatric physiotherapists in Spain, the average age at which CP was suspected was 12.6 months. To evaluate and diagnose the risk of CP, most physiotherapists; stated that they used the child's clinical history (88.1%), AIMS (41.3%) and Vojta Assessment Procedure (32.1%). In Spain, physiotherapists were found to rarely use GMs (25.7%) and HINE (28.4%). These results showed that pediatric physiotherapists in Spain rely on clinical history and older tools to identify children with CP.In this study, it was aimed to determine the awareness levels about the importance of the use of these tools in terms of early diagnosis and intervention in CP in Turkey, the frequency of use and the reasons for the obstacles if they cannot be used. In this context, the awareness levels of physiotherapists in Turkey will be determined through a digital survey administered digitally to pediatric physiotherapists in Spain and translated into Turkish after obtaining the necessary permissions.

Keywords
Cerebral Palsy, Early Detection, tools, Pediatric Physiotherapists
Medical subject headings
Cerebral Palsy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT06531330
Study groupRoleWhat they receive
1Pediatric physiotherapists working in Turkey

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Digital survey

    Digital survey: Purpose-developed digital survey consisting of 45 multiple choice questions with 5 thematic sections. The survey to be used in this context will be a survey administered digitally to pediatric physiotherapists in Spain and translated into Turkish after obtaining the necessary permissions. This survey will be administered via Google forms.Pediatric physiotherapists working in different clinics will be asked to fill out a purpose-built electronic survey online. All survey questions will be delivered to physiotherapists electronically via social media (Whatsapp, Instagram, Facebook) or e-mail. Pediatric physiotherapists from at least 20 different provinces in Turkey will participate in this study.

    The survey measure will be assessed at the baseline of the study for one time.

    Measured: The baseline of the study for one time

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Aug 2024
  2. Study start1 Mar 2023
  3. Primary completion15 Apr 2024
  4. Study completion15 Apr 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Retrospective
Enrolment
140 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06531330
Sponsor's protocol ID
KahramanmarasSIU2
Acronym
tooluse
Status last verified
Jul 2024
First submitted
24 Jul 2024
Last updated
1 Aug 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Cerebral Palsy and Early Developmental Impairment, run by Kahramanmaras Sutcu Imam University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 1 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Digital survey (time frame: The baseline of the study for one time). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Aug 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in